PENTABASE A/S
Core data
Name | PENTABASE A/S |
Address | Petersmindevej 1A, 5000, Odense C |
Founded | Jan 8, 2007 |
| 37 / 27 | |
Locations (P-units) | 1View locations |
Website | https://pentabase.com/ |
| 5Base | |
| pentabase-a-s | |
Branch | Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000) |
Name | PENTABASE A/S |
Address | Petersmindevej 1A, 5000, Odense C |
Founded | Jan 8, 2007 |
| 37 / 27 | |
Locations (P-units) | 1View locations |
Website | https://pentabase.com/ |
| 5Base | |
| pentabase-a-s | |
Branch | Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000) |
Keep track of PENTABASE A/S
Description
PentaBase is a Danish, science-driven IVD company developing and producing sensitive and specific PCR assays, diagnostic workflows, and PCR analyses using proprietary INA® DNA analogue technology for oncology and haematology diagnostics.
PentaBase develops and produces innovative PCR solutions and provides genetic analyses and services for precise detection and monitoring of genetic biomarkers, including CE-IVD certified oncology and haematology assays.
Company's own description on virk.dk
PentaBase A/S is a knowledge-driven organization committed to maintaining the highest scientific and ethical standards. We exclusively develop and provide products and services where there is strong clinical evidence supporting the relevance of the underlying biomarkers. Our mission is to advance precision medicine by delivering innovative molecular diagnostic solutions that improve patient stratification, treatment selection, and disease monitoring. Our activities are centered around proprietary DNA technologies and a comprehensive portfolio of molecular diagnostic products supporting the detection, characterization, and monitoring of cancer-related genetic and epigenetic biomarkers. In addition, we collaborate with research institutions, hospitals, and industrial partners by making our proprietary DNA platform technologies available for research and development within molecular diagnostics and life sciences. During 2025, PentaBase continued to strengthen its strategic focus on oncology diagnostics while advancing the commercialization of recently launched technologies and expanding collaborations with international clinical and research partners. Significant efforts have also been dedicated to further developing the Company's proprietary technology platforms and protecting its intellectual property portfolio. Management is satisfied with the Company's development during 2025. The financial performance improved significantly compared with the previous year, reflecting increased commercial activity, continued cost discipline, and a stronger operational foundation for future growth. Management continues to integrate environmental and social responsibility into the Company's decision-making processes. Our facilities include a rooftop solar energy installation, electric vehicle charging stations, and initiatives encouraging sustainable transportation, including cycling and the transition to electric vehicles. Together with customers and suppliers, we continue working to reduce our environmental footprint through improved recycling initiatives and by minimizing the use of plastic and polystyrene packaging materials.
Products & services
Oncology IVD PCR assays · Haematology IVD PCR assays · Custom oligonucleotides · EpiDirect® MGMT Methylation qPCR Assay · MicroSight® MSI · PlentiPlex™ MYD88, CE IVD · EpiDirect® MLH1 · Genetic analyses and services · INA® technology
Industries
Healthcare · Manufacturing
Customer types
Clinical laboratories · Healthcare professionals · Qualified laboratory personnel · Research and clinical labs
Financials
| Reporting period | 2025DKK | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross profit | 10,461,737 | ||||||||
| Operating profit | -5,712,008 | ||||||||
| Profit before tax | -1,177,610 | ||||||||
| Net income | -892,430 | ||||||||
| Total assets | 55,274,233 | ||||||||
| Equity | 53,182,584 | ||||||||
| Avg. employees | 24 | ||||||||
2017–2025 Unlock financial history | |||||||||
Datapublica Risk Score
What goes into the assessment
Financials
Equity ratio, profitability, and liquidity
Accounts and history
Late filings and previous financial distress
Owners and management
Past bankruptcies and owners’ other companies
Company and connections
Age, industry, and shared addresses or contact details
Standard: Score and risk bandPro: Also a detailed explanation of the factors
Gazelle
Loading gazelle status…
Børsen Gazelle is Dagbladet Børsen's award. Datapublica is not affiliated with Børsen. Calculated statuses are Datapublica's own analysis of public CVR financial-statement data.
People
| Person | Roles | Titles |
|---|---|---|
| Anne Gerhart-Hines | Roles Board | TitlesBESTYRELSESMEDLEM |
| Hans Christian Rohde | Roles Board | TitlesFORMAND |
| Søren Boe | Roles Board | TitlesBESTYRELSESMEDLEM |
| Torben Storgaard Guldberg | Roles Board | TitlesBESTYRELSESMEDLEM |
| Ulf Bech Christensen | Roles BoardManagement | TitlesBESTYRELSESMEDLEM • ADM. DIR. |
Auditor
| Audit firm | Auditor | Role | From |
|---|---|---|---|
| BDO Statsautoriseret Revisionspartnerselskab | AuditorMikkel Aalykke | RoleState Authorised Public Accountant | FromJun 30, 2026 |
| BDO Statsautoriseret Revisionspartnerselskab | Auditor— | Role— | FromJun 30, 2026 |
Legal owners
| Owner | Ownership | Voting rights | From |
|---|---|---|---|
| Ownership66.67–89.99 % | Voting rights66.67 % | FromMar 29, 2020 | |
| Ownership5–9.99 % | Voting rights0 % | FromDec 19, 2025 |
Child companies
| Company | Ownership | Voting rights | From |
|---|---|---|---|
| Ownership100 % | Voting rights100 % | FromJun 5, 2026 |
Ultimate owners
| Name | Ownership through | Calculated ownership |
|---|---|---|
| Ulf Bech Christensen | Ownership through | Unknown stake |